Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection

Guaraldi, Giovanni; Rossotti, Roberto; Verucchi, Gabriella; Tavio, Marcello; Pasulo, L.; Beghetto, Barbara; Dolci, Giovanni; Nardini, Giulia; Badia, Lorenzo; Magliano, Anna; Moioli, Maria Cristina; Puoti, Massimo; Hiv,

doi:10.1093/ofid/ofx065

Cited by 10 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients receiving SMV, some antiretroviral agents are contraindicated, including cobicistat-based regimens, efavirenz, etravirine, nevirapine, ritonavir, and any HIV protease inhibitor, boosted or not by ritonavir. In the recent EASL guideline, SMVcontaining regimens are not recommended but based on 2016 version of this guideline, a combination of SOF plus SMV is appropriate just for genotype 4 in HCV monoinfected or HIV/HCV co-infected patients without cirrhosis or with compensated cirrhosis (52)(53)(54).…”

Section: Sofosbuvir Plus Simeprevirmentioning

confidence: 99%

“…Sofosbuvir is available at the dose of 400 mg (one tablet) and consumed once per day. There are no potential drug-drug interactions between SOF and antiretroviral drugs but in patients with severe renal impairment is contraindicated (53,55). Combination of SOF plus RBV as an independent regimen for treatment of HCV infection was available in previous EASL guideline, but in 2018 version, this regimen is not available.…”

Section: Sofosbuvir Plus Ribavirinmentioning

confidence: 99%

“…Combination of SOF plus RBV as an independent regimen for treatment of HCV infection was available in previous EASL guideline, but in 2018 version, this regimen is not available. However, none of these guidelines suggested this combination for patients with HIV/HCV co-infection (53,54). Meanwhile, based on study assessments, this combination could not achieve acceptable SVR.…”

Section: Sofosbuvir Plus Ribavirinmentioning

confidence: 99%

“…Based on the pharmacokinetic analysis in HCVinfected population, cirrhosis (compensated and decompensated) cannot cause a clinically relevant effect on the exposure to LDV. This regimen can be used in patients with mild or moderate renal impairment without dose adjustment, but the safety of the SOF/LDV combination has not been assessed in patients with severe renal impairment (53,56). The SOF/LDV combination may be considered an effective regimen for patients with HCV mono-infection or HIV/HCV co-infection (16,57).…”

Section: Sofosbuvir/ledipasvirmentioning

confidence: 99%

“…A daily dose of DCV should be adjusted to 30 mg with atazanavir/ritonavir and cobicistatcontaining antiretroviral regimens and increase to 90 mg per day with efavirenz (an enzyme inducer). Also, using etravirine and nevirapine, both enzyme inducers, with DCV containing regimen are not recommended, and it may require a dosage adjustment, altered timing of administration or additional monitoring (53,54). As shown in Table 1 the SVR rate in patients receiving SOF plus DCV is remarkable.…”

Section: Sofosbuvir Plus Daclatasvirmentioning

confidence: 99%

See 4 more Smart Citations

Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review

et al. 2018

View full text Add to dashboard Cite

Context: Hepatitis C virus (HCV) infection is a significant cause of chronic liver disease in patients with human immunodeficiency virus (HIV) infection. Introduction of HCV direct-acting antiviral agents (DAAs) revolutionized the treatment of hepatitis C in patients with HIV/HCV co-infection. In this study, we systematically reviewed the treatment of chronic HCV infection in patients with HIV/HCV co-infection. Evidence Acquisition: In this systematic review, electronic databases including PubMed, Scopus, ScienceDirect, and Web of Science were comprehensively searched using appropriate strategies containing all related keywords of "HCV", "HIV" and "DAA". Studies assessed the effectiveness of interferon-free HCV antiviral therapies in patients with HIV/HCV co-infection were evaluated for inclusion in the systematic review. Results: After the screening of 728 records, we included 33 articles in our study, and seven different HCV antiviral regimens were evaluated. Ten studies for sofosbuvir plus simeprevir (SVR ranged from 72.2% to 100%), eight studies for sofosbuvir plus ribavirin (SVR ranged from 51.6% to 91.6%), 12 studies for sofosbuvir/ledipasvir (SVR ranged from 88.8% to 100%), eight studies for sofosbuvir plus daclatasvir (SVR ranged between 84.6% and 100%), two studies for grazoprevir/elbasvir (SVR ranged from 86.6% to 96.5%), six studies for ombitasvir/paritaprevir/ritonavir plus dasabuvir (SVR ranged from 90.6% to 100%), and just one study for sofosbuvir/velpatasvir with 95.2% SVR rate. Conclusions: This study found that treatment of HCV infection with DAAs can result in high SVR rate in patients with HIV/HCV co-infection.

show abstract

Section: Sofosbuvir Plus Simeprevirmentioning

confidence: 99%

Section: Sofosbuvir Plus Ribavirinmentioning

confidence: 99%

Section: Sofosbuvir Plus Ribavirinmentioning

confidence: 99%

Section: Sofosbuvir/ledipasvirmentioning

confidence: 99%

Section: Sofosbuvir Plus Daclatasvirmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review

et al. 2018

View full text Add to dashboard Cite

show abstract

Peritransplant Antiviral Treatment of Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Patients

Vinaixa

Aguilera

Blanes³

et al. 2018

Liver Transpl

View full text Add to dashboard Cite

TO THE EDITOR:The availability of direct-acting antivirals (DAAs) has transformed the treatment scenario in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)coinfected patients with sustained virological response (SVR) results over 90%-95%. In the peritransplant setting, there are few real-world experiences in treating patients with HIV/HCV coinfection.Our aims were to describe the outcomes of antiviral treatment with DAA in HIV/HCV-coinfected patients in terms of efficacy, safety, and drug-drug interactions (DDIs) in the pretransplant (waiting list [WL]) and posttransplant settings and to compare these results to HCV-monoinfected patients. MethodsWe conducted a retrospective and observational case-control study in a single center, Hospital Universitario y Politécnico La Fe (Valencia, Spain), which was approved by the local institutional review board. All HIV/HCV-coinfected patients who initiated HCV antiviral treatment with interferon (IFN)-free regimens from March 2014 to March 2016 either on the WL for liver transplantation (LT) or after LT were included. Each HIV/HCV-coinfected patient was matched with 2 HCV-monoinfected patients by HCV genotype (when possible), fibrosis stage, and treatment regimen, and, in the case of cirrhosis, with Model for End-Stage Liver Disease (MELD) and Child-Pugh scores.Treatment regimen choice was based on drug availability at each time point, as given by compassionate-use programs and progressive drug commercialization.Data were collected per local standard of care and at different time points: baseline (pretreatment), ontreatment (weeks 4, 12, and 24), and after treatment (weeks 4, 12, 24, and 48). Patients were followed up to 2 years since treatment initiation.For the descriptive analysis, quantitative variables are presented as median and/or mean and interquartile ranges (IQRs) or range, while categorical variables are presented as frequencies and percentages. Differences between categorical variables were assessed by chisquare test. Continuous variables were compared using the Student t test. All data were analyzed using STATA, version 12 (Stata Corp., College Station, TX). ResultsNine HIV/HCV-coinfected patients on the WL for LT were included, matched to 18 HCV-monoinfected patients in the control group. A total of 14 HIV/HCVcoinfected LT recipients with HCV recurrence receiving 15 antiviral treatments (1 patient was retreated after relapse) were included, matched to 30 HCVmonoinfected patients in the control group. Baseline features of pretransplant and posttransplant patients are summarized in Table 1. Notably, 11% of patients included (8/45) received a sofosbuvir (SOF) + ribavirin (RBV) regimen, which is not currently the recommended standard of care but was the only available regimen at the moment (see Table 1).

show abstract

The Use of Grafts from HCV+ Patients in Transplantation: Are we There Yet?

Flamm

2019

Curr Hepatology Rep

View full text Add to dashboard Cite

Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection

Cited by 10 publications

References 11 publications

Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review

Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review

Peritransplant Antiviral Treatment of Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Patients

The Use of Grafts from HCV+ Patients in Transplantation: Are we There Yet?

Contact Info

Product

Resources

About